Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

Kathleen M. Dungan MD, MPH Advisory Board

See All Experts

story of the week

Published in Diabetes and

Journal Scan / Research · April 22, 2019

Canagliflozin Improves Renal Outcomes in Type 2 Diabetes

The New England Journal of Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Steven Coca DO, MS

The New England Journal of Medicine

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

N. Engl. J. Med 2019 Apr 14;[EPub Ahead of Print], V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, DM Charytan, R Edwards, R Agarwal, G Bakris, S Bull, CP Cannon, G Capuano, PL Chu, D de Zeeuw, T Greene, A Levin, C Pollock, DC Wheeler, Y Yavin, H Zhang, B Zinman, G Meininger, BM Brenner, KW Mahaffey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Canagliflozin Improves Renal Outcomes in Type 2 Diabetes

Additional Info

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Further Reading

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Recently Updated